CN101935665A - Recombinant protein A gene and preparation method and application of expression product thereof - Google Patents
Recombinant protein A gene and preparation method and application of expression product thereof Download PDFInfo
- Publication number
- CN101935665A CN101935665A CN2010102450048A CN201010245004A CN101935665A CN 101935665 A CN101935665 A CN 101935665A CN 2010102450048 A CN2010102450048 A CN 2010102450048A CN 201010245004 A CN201010245004 A CN 201010245004A CN 101935665 A CN101935665 A CN 101935665A
- Authority
- CN
- China
- Prior art keywords
- recombinant protein
- protein
- gene
- pet32a
- recombined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 91
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 79
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 45
- 238000000746 purification Methods 0.000 claims abstract description 19
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 18
- 229920002684 Sepharose Polymers 0.000 claims abstract description 17
- 239000012501 chromatography medium Substances 0.000 claims abstract description 17
- 239000013604 expression vector Substances 0.000 claims abstract description 15
- 238000000926 separation method Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 241000672609 Escherichia coli BL21 Species 0.000 claims abstract description 3
- 235000018102 proteins Nutrition 0.000 claims description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 108091008146 restriction endonucleases Proteins 0.000 claims description 18
- 239000000499 gel Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000178 monomer Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- XAEWTDMGFGHWFK-IMJSIDKUSA-N Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O XAEWTDMGFGHWFK-IMJSIDKUSA-N 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims description 2
- OBTCMSPFOITUIJ-FSPLSTOPSA-N Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O OBTCMSPFOITUIJ-FSPLSTOPSA-N 0.000 claims description 2
- 239000011543 agarose gel Substances 0.000 claims description 2
- 108010041407 alanylaspartic acid Proteins 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 6
- 230000027455 binding Effects 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 5
- 238000003259 recombinant expression Methods 0.000 abstract description 5
- 230000009182 swimming Effects 0.000 description 21
- 239000000872 buffer Substances 0.000 description 13
- 206010003445 Ascites Diseases 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000013256 coordination polymer Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940023064 escherichia coli Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012474 protein marker Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 101710153593 Albumin A Proteins 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 101150065015 spa gene Proteins 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention provides a recombinant protein A gene which has the nucleotide sequence shown in SEQ ID NO: 1, and a recombinant protein A coded by the gene. The invention also provides a recombinant expression vector PET32a-P for expressing the recombinant protein A gene, escherichia coli BL21/DE3 transformed by the recombinant expression vector PET32a-P, and a method for preparing the recombinant protein A. The recombinant protein A provided by the invention is used for antibody detection, separation and purification, and can form an affinity chromatography medium together with a chromatography medium carrier. The recombinant protein A produced by the invention has the advantages of strong protein binding specificity, high affinity and greatly improved purification efficiency, and compared with the commercial protein A Sepharose 4Fast Flow, the dynamic adsorption capacity of the recombinant protein A is obviously improved.
Description
The present invention for denomination of invention is: the preparation method of a kind of A gene of recombined protein and expression product thereof and purposes, application number is: the dividing an application of the Chinese patent application of 200710085148.X.
Technical field
The invention belongs to biological technical field, specifically, relate to a kind of A gene of recombined protein, and contain the carrier of this recombination, the bacterial strain and the A gene of recombined protein expressed products of conversion, and its production and use.
Background technology
(Staphylococal Protein A is a kind of from the isolating protein of aureus cell wall SPA) to SP.1940, Vevwey found to contain a kind of material in some streptococcus aureus, in double diffusion test, can form precipitation with normal human serum.Jensen (1959) has also found similar phenomenon, with its called after A antigen.
Lofkvist in 1963 etc. have separated A antigen, and prove that it is a kind of protein, and have any different with sugar; Grov (1960) is called for short SPA albumin A (ProteinA) with its called after SP.The gene of coding SPA was cloned and at expression in escherichia coli (Duggleby in nineteen eighty-three, C.J and Jones, SA:cloning and expression of the Staphylococcus aureus protein A gene in Escherichiacoli.Nucl Acids Res.11 (1983) 3065-3076; Lofdahl, S., Guss, B., et al; Gene forStaphylococcal protein A.Proc.Natl.Acid.Sci.USA 80 (1983) 697-701).To discovering of SPA 26S Proteasome Structure and Function, the SPA molecule comprises A, B, C, D, five homeodomains of E, each structural domain all have can with the autonomous bonded ability of IgG.The SPA gene has 1600bp.
Owing to have 5 structural domains to combine on the SP, have Fc section bonded ability with most of Mammals IgG with the Fc district of IgG.As a kind of affinity ligand, albumin A is fixed on above the agarose, and 5 structural domains above it just can freely combine with the Fc of IgG, and a part fixed albumin A can combine with bimolecular IgG, its C end of recombinant protein A has a Gelucystine, and is stronger in conjunction with the ability of IgG.Recombinant protein A is widely used in the separation and purification and the detection of monoclonal antibody or polyclonal antibody.When use contains the affinity chromatography technology of proteinA, there are problems such as avidity is low, purification efficiency is low, therefore when this affinity chromatography technology of use, need a kind of improved ProteinA, realize higher avidity, improve the effect of purifying.
Summary of the invention
One of technical issues that need to address of the present invention provide a kind of gene order of new recombinant protein A, to overcome the deficiencies in the prior art.
Two of the technical issues that need to address of the present invention provide the aminoacid sequence of this recombinant protein A, to overcome the deficiencies in the prior art.
Three of the technical issues that need to address of the present invention provide the carrier that contains this A gene of recombined protein.
Four of the technical issues that need to address of the present invention provide the expression vector transformed host cell that is contained A gene of recombined protein.
Five of the technical issues that need to address of the present invention provide the preparation method of this recombinant protein A.
Six of the technical issues that need to address of the present invention provide the purposes of this recombinant protein A.
Seven of the technical issues that need to address of the present invention provide a kind of affinity chromatography medium of being made up of this recombinant protein A and chromatography media carrier.
Technical scheme of the present invention is as follows:
A gene of recombined protein provided by the invention is to be connected in series with 3 artificial synthetic A gene of recombined protein monomers, 5 ' hold Ala-Asp to be mutated into Val-Asp, to form AccI restriction enzyme site (GTAGAC), link to each other with the AccI restriction enzyme site between each A gene of recombined protein monomer, wherein first A gene of recombined protein monomer front end adds the NcoI restriction enzyme site that links to each other with expression vector, 6 His (are used for affinity chromatography, combine with the nickel post, reduce purification step) and the EK restriction enzyme site (His and DDDDK are cut, form correct ProteinA), last A gene of recombined protein monomer is ended codon TAA and the BamH I restriction enzyme site that links to each other with expression vector pET32a terminal the adding.This gene is made of 621 Nucleotide, 180 amino acid of encoding.This gene order and amino acid sequence coded thereof are seen sequence table SEQ ID No.1 and SEQ ID No.2.
The present invention has also made up the carrier that contains above-mentioned A gene of recombined protein, these construction of carrier are according to ordinary method, to cut between the corresponding restriction enzyme site that inserts respective carrier in the back by the A gene of recombined protein monomeric enzyme of synthetic, again with Acc I endonuclease digestion, connect into and comprise the monomeric A gene of recombined protein expression vector of a plurality of polyphone A gene of recombined protein.
The recombinant expression vector that the above-mentioned coli expression carrier that contains A gene of recombined protein preferentially is built into by synthetic A gene of recombined protein of the present invention and coli expression carrier PET32, called after pET32a-P.
The present invention also provides the method for utilizing the above-mentioned intestinal bacteria recombinant strain that contains the intestinal bacteria recombinant expression vector to produce recombinant protein A, this method is bacterial classification to be carried out cultivation and fermentation make its highly effective expressing recombinant protein A, regather thalline, obtain the recombinant protein A product through separation and purification.
The coli strain of the above-mentioned energy of the present invention express recombinant protein A is preferably the bacterial strain that is obtained by the expression vector pET32a-P transformed into escherichia coli BL21/DE3 that contains A gene of recombined protein, called after BL21/pET32a.
The recombinant protein A that the present invention produces is expressed in the Escherichia coli cell pericentral siphon, helps the separation and purification of expression product.Utilize the present invention to express the production recombinant protein A, have the expression efficiency height, expression amount big (accounting for the 60-80% of bacterium total soluble protein), is easy to advantages such as purifying at expression time short (only 3-5 hour).
The present invention adopts escherichia expression system to produce recombinant protein A, also has (1 day) with short production cycle, and the characteristics that production cost is low help the commercial application of genetically engineered recombinant protein A.
The expression product recombinant protein A of A gene of recombined protein of the present invention is used for becoming the separation and purification that affinity chromatography medium is used for antibody with various chromatography media carrier as couplings such as: sepharose, dextran, Mierocrystalline cellulose, hydroxyl high molecular polymer, silica gel.
The recombinant protein A that the present invention produces has the protein binding high specificity, and the advantage that avidity height, purification efficiency improve is greatly compared with commercially available ProteinA Sepharose 4Fast Flow, and its dynamic adsorption carrying capacity obviously improves.
Description of drawings
Fig. 1 is the recombinant expression vector pET32a-P that the present invention makes up, and is to be connected into the proteinA gene in carrier pET32a.
Fig. 2: the SDS-PAGE gel electrophoresis result of thalline, wherein swimming lane 1 and 5 is marker; Swimming lane 2 is empty carriers; Swimming lane 3 is the supernatants behind the broken bacterium of inductive BL21/pET32a; Swimming lane 4 is the precipitations behind the broken bacterium of inductive BL21/pET32a.
Fig. 3: recombinant protein A sepharose 5S CP separation and purification IgG2aSDS-PAGE electrophoresis result from mouse ascites: swimming lane 1 is standard protein Marker, swimming lane 2 is an ascites, and swimming lane 3 is the elution peak of recombinant protein A sepharose 5S CP affinity media of the present invention.
Fig. 4: the recombinant protein A dextrane gel is separation and purification IgG2aSDS-PAGE electrophoresis result from mouse ascites: swimming lane 1 is standard protein Marker, swimming lane 2 is an ascites, the elution peak of the pillar that swimming lane 3 is adorned for recombinant protein A dextrane gel affinity media of the present invention.In the swimming lane 3, heavy chain and light chain that upper and lower two bands are respectively IgG2a.
Embodiment
Embodiment 1 A gene of recombined protein is monomeric synthetic
Method by chemosynthesis, the sequence of the synthetic repeated fragment of A gene of recombined protein of design, its sequence comprises that length is 168bp, front end adds the NcoI restriction enzyme site that links to each other with expression vector, 6 His (are used for affinity chromatography, combine with the nickel post, reduce purification step) and the EK restriction enzyme site, and the AccI restriction enzyme site that is used to be connected into a plurality of repeated fragments.In addition, also comprise terminator codon TAA, and the clone is total to 9bp with BamH I restriction enzyme joint.Also must be by the method for chemosynthesis, the sequence of the synthetic repeated fragment of A gene of recombined protein of design, its sequence comprises that length is 168bp, two ends are the AccI restriction enzyme site, are used to make up the sequence that contains a plurality of repeated fragments.
With restricted type restriction endonuclease NcoI and BamH I above-mentioned A gene of recombined protein monomer is downcut, be connected with the carrier pET32a that cuts through NcoI and BamHI enzyme, transformed into escherichia coli, screening has the transformant of amicillin resistance, extract through plasmid, enzyme is cut and is identified that back proof A gene of recombined protein monomer is cloned among the pET32a.
Contain a monomeric pET32a carrier of A gene of recombined protein and the A gene of recombined protein monomer is cut with the AccI enzyme with above-mentioned, connect after reclaiming respective segments, transformed into escherichia coli, screening has the transformant of amicillin resistance, extract through plasmid, enzyme is cut the pET32a-P carrier that screening obtains to contain 3 monomeric recombinant protein As of protein A gene.
The structure of the coli strain BL21/pET32a of embodiment 4 express recombinant protein A
With the CaCl2 method pET32a-P is transformed BL21/DE3, screen transformant containing on the LB flat board of penbritin, detect and the restriction analysis acquisition contains the sub-BL21/pET32a of recombinant conversion of pET32a through plasmid.
1) culture of strains fermentation
Picking colibacillus engineering BL21/pET32a, be inoculated in the LB substratum, inoculum size 1～2%V/V, in 30 ℃ of overnight incubation, next day under aseptic condition with above-mentioned cultured seed substratum by 1: 10-1: 5 are inoculated on the fermention medium, 30 ℃ ferment to O.D600 and reach 0.4～0.8, are warming up to 42 ℃ and induce, centrifugal receipts bacterium after 3～5 hours;
The cell that takes a morsel adds 2 * sample-loading buffer, do the SDS-PAGE gel electrophoresis by standard, result such as Figure of description 2, supernatant behind the broken bacterium of inductive BL21/pET32a a new protein band (seeing Fig. 2 swimming lane 3) occurs in the position of 20kD, transform in the BL21/DE3 bacterium of PET32 empty carrier and the precipitation behind the broken bacterium of inductive BL21/pET32a and this band (seeing Fig. 2 swimming lane 2 and 4) do not occur, prove that the egg of recombinating induced soluble-expression from A in BL21/pET32a.
2) purifying of the recombinant protein A of Biao Daing
Above-mentioned collection thalline is suspended with NaCl ten phosphate buffered saline buffers (pH7.0-8.0), ultrasonication, 4 ℃ are centrifugal, collect supernatant, get crude extract.
Show through the SDS-PAGE electrophoresis detection, it is fine to extract the recombinant protein A effect that is expressed in the Escherichia coli cell pericentral siphon with this law, slightly carrying the most of recombinant protein A in back is slightly carried, the amount that remains in thalline is atomic: crude extract is carried out Sephacryl 5200 molecular sieve purification, collect the recombinant protein A that characteristic peak (second elution peak) is purifying, its purity can reach more than 90%.
Embodiment 6 ELISA methods detect the test of recombinant protein A and antibody binding activity
1) bag quilt: every hole bag is by recombinant protein A sample 100u l, 37 ℃, 1h in 96 orifice plates;
2) sealing: every hole is with 1% the BSA sealing of 100u l, 37 ℃, 1h;
3) adding one resists: every hole adds about 100ug human IgG antibody, 37 ℃, 1h;
4) adding two resists: every hole adds about 100u l1: 1000 horseradish peroxidase-labeled antibody, 37 ℃, 1h;
5) colour developing.
Detect through ELISA that to show that recombinant protein A that the present invention extracts and human IgG antibody combine activity strong, wrap in every hole can be obtained tangible detection signal by the 4.5ng recombinant protein A, and the result shows that recombinant protein A provided by the invention can be used for detection of antibodies.
The preparation of embodiment 7 recombinant protein A sepharose 5S CP
1, react in water medium with epoxy chloropropane, sodium hydroxide and agarose (5% cross-linked agarose gel), reaction is 2-3 hour under 30-60 ℃ temperature, has reacted back the cleaning to neutrality with distilled water and has drained;
2, above-mentioned product and recombinant protein A of the present invention were reacted 15-20 hour under 5-25 ℃ of temperature, reacted the back cleaning and drained again, promptly obtain recombinant protein A sepharose 5S CP
Recombinant protein A sepharose 5S CP has following characteristic:
1) characteristics: group comes off few, and binding specificity is strong;
2). aglucon density: ≈ 6mg recombinant protein A/ml;
3) absorption carrying capacity: 3～30mg mouse IgG2a/ml;
4) granular size of affinity media: 30-180 μ m;
5) Peak Flow Rate: 250cm/h
6) pH scope: 2-11;
7) storage temperature: 4-8 ℃;
8) preserve liquid: 20% ethanol.
If the adsorptive power between antibody purified to be separated and affinity chromatography medium is more weak, then can suitably improve the pH value and the salt concn of adsorption-buffering liquid, can obtain separating effect preferably.
Embodiment 8 recombinant protein A sepharose 5S CP separation and purification IgG2a from mouse ascites
1, recombinant protein A sepharose 5S CP dress post, 1.6 * 20cm, column volume are 10ml;
2, with buffer A (20mM phosphate buffered saline buffer, pH7.4, i.e. the PBS solution of pH7.4.Preparation: 0.2M NaH
2PO
419ml, 0.2M Na
2HPO
481ml, NaCl 9g adds water to 1000ml.) a balance 5-10 bed volume, flow velocity is 1ml/min;
3, the 2ml mouse ascites is diluted to 20ml with buffer A, 0.45 μ m membrane filtration, last sample.Flow velocity is 1ml/min;
4, wash 5-10 bed volume again with buffer A, flow velocity is 1ml/min;
5, with buffer B (20mM citrate buffer solution, pH4.0.Preparation: citric acid 2.1g adds water 950ml, transfers to pH 4.0 with 5M NaOH, adds water to 1000ml) wash-out, flow velocity is 1ml/min, collects elution peak;
6, wash 10 column volumes with pure water stream, wash 10 column volumes with 20% ethanol stream again, flow velocity is 2ml/min, and pillar places 4-8 ℃ of environment to preserve;
7, IgG2a and the reference substance with separation and purification carries out the SDS-PAGE electrophoretic analysis simultaneously; (should be after the every use several times of pillar in order to damping fluid C (0.5M acetate buffer solution, pH3.0.Preparation: the 0.5M acetum transfers to pH 3.0 with solid NaOH) stream washes 1 time, so that will adsorb more firm albumen removal.) result:
The SDS-PAGE electrophoretic analysis the results are shown in Figure 3, and swimming lane 1 is standard protein Marker, and swimming lane 2 is an ascites, the elution peak of the pillar that swimming lane 3 is adorned for recombinant protein A sepharose 5S CP affinity media of the present invention.In the swimming lane 3, heavy chain and light chain that upper and lower two bands are respectively IgG2a.Test-results has shown that recombinant protein A sepharose 5S CP affinity chromatography medium of the present invention can obtain purity greater than 95% IgG2a once going on foot.
The preparation of embodiment 9 recombinant protein A dextrane geles
1, react in water medium with epoxy chloropropane, sodium hydroxide and dextrane gel, reaction is 2-3 hour under 30-60 ℃ temperature, has reacted back the cleaning to neutrality with distilled water and has drained;
2, above-mentioned product and recombinant protein A of the present invention were reacted 15-20 hour under 5-25 ℃ of temperature, reacted the back cleaning and drained again, promptly obtain the recombinant protein A dextrane gel.
The recombinant protein A dextrane gel has following characteristic:
1) characteristics: group comes off few, and binding specificity is strong;
2) aglucon density: ≈ 6mg recombinant protein A/ml;
3) absorption carrying capacity: 3～30mg mouse IgG2a/ml;
4) granular size of affinity media: 20-130 μ m;
5) Peak Flow Rate: 200cm/h
6) pH scope: 2-11;
7) storage temperature: 4-8 ℃;
8) preserve liquid: 20% ethanol.
If the adsorptive power between antibody purified to be separated and affinity chromatography medium is more weak, then can suitably improve the pH value and the salt concn of adsorption-buffering liquid, can obtain separating effect preferably.
Embodiment 10 recombinant protein A dextrane geles separation and purification IgG2a from mouse ascites
1, recombinant protein A dextrane gel dress post, 1.6 * 20cm, column volume are 10ml;
2, with buffer A (20mM phosphate buffered saline buffer, pH7.4, i.e. the PBS solution of pH7.4.Preparation: 0.2M NaH
2PO
419ml, 0.2M Na
2HP0481ml, NaCl 9g adds water to 1000ml.) a balance 5-10 bed volume, flow velocity is 1ml/min;
3, the 2ml mouse ascites is diluted to 20ml with buffer A, 0.45 μ m membrane filtration, last sample.Flow velocity is 1ml/min;
4, wash 5-10 bed volume again with buffer A, flow velocity is 1ml/min;
5, with buffer B (20mM citrate buffer solution, pH4.0.Preparation: citric acid 2.1g adds water 950ml, transfers to pH 4.0 with 5M NaOH, adds water to 1000ml) wash-out, flow velocity is 1ml/min, collects elution peak;
6, wash 10 column volumes with pure water stream, wash 10 column volumes with 20% ethanol stream again, flow velocity is 2ml/min, and pillar places 4-8 ℃ of environment to preserve;
7, IgG2a and the reference substance with separation and purification carries out the SDS-PAGE electrophoretic analysis simultaneously;
(should be after the every use several times of pillar in order to damping fluid C (0.5M acetate buffer solution, pH3.0.Preparation: the 0.5M acetum transfers to pH 3.0 with solid NaOH) stream washes 1 time, so that will adsorb more firm albumen removal.) result:
The SDS-PAGE electrophoretic analysis the results are shown in Figure 4, and swimming lane 1 is standard protein Marker, and swimming lane 2 is an ascites, the elution peak of the pillar that swimming lane 3 is adorned for recombinant protein A dextrane gel affinity media of the present invention.In the swimming lane 3, heavy chain and light chain that upper and lower two bands are respectively IgG2a, test-results has shown that recombinant protein A dextrane gel affinity chromatography medium of the present invention can obtain purity greater than 95% IgG2a once going on foot.
Embodiment 11 recombinant protein A sepharoses, dextrane gel and commercially available ProteinA Sepharose 4Fast Flow compare the mensuration of human IgG1's dynamic adsorption carrying capacity
1, with buffer A (20mM phosphate buffered saline buffer, pH7.4, i.e. the PBS solution of pH7.4.Preparation: 0.2M NaH
2PO
419ml, 0.2M Na
2HP0
481ml, NaCl 9g adds water to 1000ml.) a balance 5-10 bed volume, flow velocity is 1ml/min;
2, concentration known human IgG1 (obtaining by disclosed embodiment among the Chinese invention patent 01132225.X) goes up sample, and flow velocity is 1ml/min, stops when 10% penetrates;
3, per sample concentration, go up the dynamic adsorption carrying capacity that sample volume and column volume calculate 10% each gel when penetrating.
Can judge that according to result's (seeing Table 1) recombinant protein A sepharose that this patent provides and recombinant protein A dextrane gel all are higher than commercially available ProteinA Sepharose 4FastFlow to human IgG1's dynamic adsorption carrying capacity.
Table 1: each gel IgG1 dynamic adsorption carrying capacity relatively
Claims (9)
- A kind of preparation method of recombinant protein A affinity chromatography medium is characterized in that, described preparation method may further comprise the steps:(1) synthesizes the A gene of recombined protein monomer by the method design of chemosynthesis, 5 ' hold Ala-Asp to be mutated into Val-Asp, to form the AccI restriction enzyme site, link to each other with the AccI restriction enzyme site between each A gene of recombined protein monomer, first A gene of recombined protein monomer front end adds the NcoI restriction enzyme site that links to each other with expression vector, 6 His and EK restriction enzyme site, last A gene of recombined protein monomer is ended codon TAA and the BamH I restriction enzyme site that links to each other with expression vector pET32a terminal the adding;(2) the A gene of recombined protein monomeric enzyme of step (1) is cut between the corresponding restriction enzyme site that inserts carrier pET32a in the back,, connected into and comprise 3 the monomeric A gene of recombined protein expression vector of polyphone A gene of recombined protein pET32a-P again with Acc I endonuclease digestion;(3) with the expression vector pET32a-P transformed into escherichia coli BL21/DE3 of step (2), screening, enzyme are cut, and obtain the sub-BL21/pET32a of recombinant conversion;(4) the bacterial strain BL21/pET32a with step (3) carries out cultivation and fermentation, makes its highly effective expressing recombinant protein A, regathers thalline, obtains the recombinant protein A product through separation, purifying;(5) react in water medium with epoxy chloropropane, sodium hydroxide and agarose or dextrane gel, the recombinant protein A that reaction product and step (4) obtain reacted 15-20 hour under 5-25 ℃ of temperature, react the back cleaning and drained again, obtained the recombinant protein A gel.
- Preparation method as claimed in claim 1 is characterized in that, described step (5) sepharose is 5% cross-linked agarose gel.
- Recombinant protein A as each described preparation method among the claim 1-2 obtains has the aminoacid sequence shown in the SEQ IDNO.1.
- Recombinant protein A as claimed in claim 3 has the nucleotide sequence shown in the SEQ ID NO.2.
- As the recombinant protein A affinity chromatography medium that each described preparation method among the claim 1-2 obtains, wherein recombinant protein A has the aminoacid sequence shown in the SEQ ID NO.1.
- Recombinant protein A affinity chromatography medium as claimed in claim 5, wherein recombinant protein A has the nucleotide sequence shown in the SEQ ID NO.2.
- Purposes as the recombinant protein A affinity chromatography medium of each described preparation method's acquisition among the claim 1-2 is characterized in that described recombinant protein A affinity chromatography medium is used for the antibody separation and purification.
- Purposes as each described recombinant protein A among the claim 3-4 is characterized in that described recombinant protein A is used for antibody test.
- Purposes as each described recombinant protein A affinity chromatography medium among the claim 5-6 is characterized in that, described recombinant protein A affinity chromatography medium is used for the antibody separation and purification.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010245004 CN101935665B (en) | 2006-03-17 | 2007-03-14 | Preparation method and application of recombinant protein A gene and expression product thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610024828 | 2006-03-17 | ||
| CN200610024828.6 | 2006-03-17 | ||
| CN 201010245004 CN101935665B (en) | 2006-03-17 | 2007-03-14 | Preparation method and application of recombinant protein A gene and expression product thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710085148XA Division CN101050464B (en) | 2006-03-17 | 2007-03-14 | Method for preparing A gene of recombined protein, and expressed products and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101935665A true CN101935665A (en) | 2011-01-05 |
| CN101935665B CN101935665B (en) | 2013-08-28 |
Family
ID=43389234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010245004 Active CN101935665B (en) | 2006-03-17 | 2007-03-14 | Preparation method and application of recombinant protein A gene and expression product thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101935665B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105407905A (en) * | 2014-01-03 | 2016-03-16 | 生物辐射实验室股份有限公司 | Removal of impurities from protein A eluates |
| CN113278052A (en) * | 2021-05-11 | 2021-08-20 | 平湖优谱生物技术有限公司 | Preparation method of recombinant Protein A and affinity chromatography medium |
| CN116854788A (en) * | 2023-08-31 | 2023-10-10 | 江苏百英生物科技有限公司 | Recombinant protein A and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| CN1212884C (en) * | 2001-01-17 | 2005-08-03 | 浙江科锐生物科技有限公司 | Affinity adsorption medium and its preparing medium |
| CN1432578A (en) * | 2003-02-26 | 2003-07-30 | 本元正阳基因技术股份有限公司 | Recombinant protein A gene and prepn and application of its expression product |
| CN1524957A (en) * | 2003-02-26 | 2004-09-01 | 本元正阳基因技术股份有限公司 | Recombinant protein a gene ,its expression products and use |
| CA2581208A1 (en) * | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
-
2007
- 2007-03-14 CN CN 201010245004 patent/CN101935665B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105407905A (en) * | 2014-01-03 | 2016-03-16 | 生物辐射实验室股份有限公司 | Removal of impurities from protein A eluates |
| CN105407905B (en) * | 2014-01-03 | 2020-03-03 | 生物辐射实验室股份有限公司 | Removal of impurities from protein A eluate |
| US10584150B2 (en) | 2014-01-03 | 2020-03-10 | Bio-Rad Laboratories, Inc. | Removal of impurities from protein A eluates |
| CN113278052A (en) * | 2021-05-11 | 2021-08-20 | 平湖优谱生物技术有限公司 | Preparation method of recombinant Protein A and affinity chromatography medium |
| CN113278052B (en) * | 2021-05-11 | 2022-09-09 | 博格隆(浙江)生物技术有限公司 | Preparation method of recombinant Protein A and affinity chromatography medium |
| CN116854788A (en) * | 2023-08-31 | 2023-10-10 | 江苏百英生物科技有限公司 | Recombinant protein A and application thereof |
| CN116854788B (en) * | 2023-08-31 | 2023-11-07 | 江苏百英生物科技有限公司 | Recombinant protein A and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101935665B (en) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mishkind et al. | Distribution of wheat germ agglutinin in young wheat plants | |
| Völlenkle et al. | Construction of a functional S-layer fusion protein comprising an immunoglobulin G-binding domain for development of specific adsorbents for extracorporeal blood purification | |
| EP3233891B1 (en) | Modified kappa light chain-binding polypeptides | |
| AU614718B2 (en) | A neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin | |
| CN101050464B (en) | Method for preparing A gene of recombined protein, and expressed products and application | |
| CN102329379A (en) | Recombined protein A, coding gene thereof and purpose thereof | |
| CN102115493A (en) | Preparation method for recombinant protein G and application of same | |
| CN105771940A (en) | Affinity chromatography medium, and preparation method and application thereof | |
| CN102892885A (en) | Iga-binding peptide and iga purification using same | |
| CN101935665B (en) | Preparation method and application of recombinant protein A gene and expression product thereof | |
| CN101760466B (en) | The preparation of A gene of recombined protein and expression product thereof | |
| CN103111094A (en) | Preparation and application of hexahistidine-tagged protein immunoaffinity purification and enrichment column | |
| JPH02154689A (en) | Fibronectin-combined protein and its manufacture | |
| CN103184229A (en) | Recombinant protein A/G gene and preparation and application of expression product of recombinant protein A/G gene | |
| CN106188251A (en) | A kind of immunoglobulin-binding proteins mutant and application thereof | |
| CN101337986A (en) | Artificial recombined hexon protein A, constructing method thereof and use | |
| CN1243015C (en) | Separating and purifying technology for micro algae phycoerythrin | |
| CN108570118B (en) | Affinity chromatography purification method of placenta-like chondroitin sulfate A or derivative thereof | |
| CN103242435A (en) | Compatible streptavidin mutant and preparation method thereof | |
| CN102676562A (en) | Preparation method and application of fusion protein with broad spectrum adsorption capacity to antibodies | |
| CN102329840A (en) | Preparation method of recombinant protein A | |
| CN101298475A (en) | Artificial recombinant penton protein A, construction method and use thereof | |
| CN101830975B (en) | Recombinant galectin-1 two-string protein and preparation method thereof | |
| Glurich et al. | Identification of Streptococcus pyogenes proteins that bind to rabbit kidney in vitro and in vivo | |
| SE1451564A1 (en) | Modified kappa light chain-binding polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ANTIBODIES NATIONAL ENGINEERING RESEARCH CENTER Free format text: FORMER OWNER: SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD. Effective date: 20110330 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 NO. 399, LIBING ROAD, ZHANGJIANG HIGH-TECH. PARK, PUDONG NEW DISTRICT, SHANGHAI TO: 201203 BUILDING 3, NO. 399, LIBING ROAD, ZHANGJIANG HIGH-TECH. PARK, PUDONG NEW DISTRICT, SHANGHAI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110330 Address after: Shanghai city 201203 libing road Zhangjiang High Tech Park of Pudong New Area No. 399 building 3 Applicant after: SHANGHAI NATIONAL ENGINEERING RESEARCH CENTER OF ANTIBODY MEDICINE Co.,Ltd. Address before: Shanghai city 201203 libing road Pudong New Area Zhangjiang hi tech Park No. 399 Applicant before: SHANGHAI CP GUOJIAN PHARMACEUTICAL Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221201 Address after: Room 304-17, No. 665, Zhangjiang Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, 201210 Patentee after: Shanghai Shengguo Pharmaceutical Development Co.,Ltd. Address before: Shanghai city 201203 libing road Zhangjiang High Tech Park of Pudong New Area No. 399 building 3 Patentee before: SHANGHAI NATIONAL ENGINEERING RESEARCH CENTER OF ANTIBODY MEDICINE Co.,Ltd. |